Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation
4 affiliations
- 1Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom
- 2Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
- 3MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
- 4Department of Global and Environmental Health, School of Global Public Health, New York University, New York, United States of America
Abstract
Background: COVID-19 vaccines played a critical role in reducing global health burden during the COVID-19 pandemic, but their rapid development required extraordinary effort. This study aims to evaluate their global return-on-investment (ROI) during the first year of the vaccination programme (8 December 2020–8 December 2021) to provide insights into the economic benefits relative to the costs of vaccine development, manufacturing, and delivery. Methods and findings: Public health outcomes of COVID-19 vaccination, including life years and quality-adjusted life years (QALYs) gained from averted deaths, infections, and hospitalizations, were estimated. Health benefits were valued using two approaches: i) cost-benefit analysis and ii) cost-effectiveness analysis. These benefits were compared to the costs of vaccine development, manufacturing, and delivery to estimate the ROI under both approaches. Probabilistic sensitivity analyses were conducted to assess the impact of parameter uncertainty on ROI estimates. Vaccine development and delivery cost $79.4 billion, but the health and economic benefits of vaccination were valued between $6.43 and $64.3 trillion. High-income countries saw the greatest health benefits per-person vaccinated, and low-income countries gained the greatest nonhealth benefits per-person vaccinated, when expressed as a proportion of gross domestic product per capita. This estimated ROIs of 59.7–809 per dollar invested in the base case analysis. ROIs ranged between 60.3–753 across probabilistic sensitivity analyses for both approaches. Limitations include reliance on previous analyses of COVID-19 vaccination impact and a time horizon limited to the first year of COVID-19 vaccination. Conclusions: Rapid COVID-19 vaccine development and delivery were an excellent investment. Vaccine development and equitable vaccine distribution globally should be prioritized before and during global health crises. Why was this study done?: What did the researchers do and find?: What do these findings mean?: In this model-based economic evaluation, Hallie Benjamin and colleagues compare the costs of vaccine development, manufacturing, and delivery with estimated health and economic benefits during the first year of the COVID-19 vaccination programme. The study suggests it was associated with substantial value relative to investment across countries, with estimated benefits far exceeding costs and highlighting the potential importance of vaccine development and equitable distribution during global health emergencies.
Related
- Economic evaluation of antimicrobial stewardship programme in primary care in Kosovo: study protocol
- Methodological drivers, reporting completeness, and transferability in HPV vaccination economic evaluations: A scoping review
- An impact evaluation of the Scottish take-home naloxone programme
- Evaluation of the real-world protective effect of mumps-containing vaccines among children under 15 years old in Taizhou: A 1:2 matched case-control study
- Awareness and use of ecological and economic evaluation of medical devices in healthcare centers: a survey of French hospitals
BibTeX
@article{benjamin2026global,
title = {{Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation}},
author = {Hallie Benjamin and Gregory Barnsley and Oliver J. Watson and Mark Jit},
journal = {PLOS Medicine},
year = {2026},
month = nov,
doi = {10.1371/journal.pmed.1004772},
url = {https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004772},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation
AU - Hallie Benjamin
AU - Gregory Barnsley
AU - Oliver J. Watson
AU - Mark Jit
PY - 2026
DA - 2026/11/05
JO - PLOS Medicine
DO - 10.1371/journal.pmed.1004772
UR - https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004772
AB - Background: COVID-19 vaccines played a critical role in reducing global health burden during the COVID-19 pandemic, but their rapid development required extraordinary effort. This study aims to evaluate their global return-on-investment (ROI) during the first year of the vaccination programme (8 December 2020–8 December 2021) to provide insights into the economic benefits relative to the costs of vaccine development, manufacturing, and delivery. Methods and findings: Public health outcomes of COVID-19 vaccination, including life years and quality-adjusted life years (QALYs) gained from averted deaths, infections, and hospitalizations, were estimated. Health benefits were valued using two approaches: i) cost-benefit analysis and ii) cost-effectiveness analysis. These benefits were compared to the costs of vaccine development, manufacturing, and delivery to estimate the ROI under both approaches. Probabilistic sensitivity analyses were conducted to assess the impact of parameter uncertainty on ROI estimates. Vaccine development and delivery cost $79.4 billion, but the health and economic benefits of vaccination were valued between $6.43 and $64.3 trillion. High-income countries saw the greatest health benefits per-person vaccinated, and low-income countries gained the greatest nonhealth benefits per-person vaccinated, when expressed as a proportion of gross domestic product per capita. This estimated ROIs of 59.7–809 per dollar invested in the base case analysis. ROIs ranged between 60.3–753 across probabilistic sensitivity analyses for both approaches. Limitations include reliance on previous analyses of COVID-19 vaccination impact and a time horizon limited to the first year of COVID-19 vaccination. Conclusions: Rapid COVID-19 vaccine development and delivery were an excellent investment. Vaccine development and equitable vaccine distribution globally should be prioritized before and during global health crises. Why was this study done?: What did the researchers do and find?: What do these findings mean?: In this model-based economic evaluation, Hallie Benjamin and colleagues compare the costs of vaccine development, manufacturing, and delivery with estimated health and economic benefits during the first year of the COVID-19 vaccination programme. The study suggests it was associated with substantial value relative to investment across countries, with estimated benefits far exceeding costs and highlighting the potential importance of vaccine development and equitable distribution during global health emergencies.
SN - 1549-1676
ER -